Regulatory status (June 2026): Not approved by any regulatory authority
A natural question might be, is there a substantial difference between the GLP-1s approved to treat T2D versus weight loss
These include cases of pancreatitis and a potential association with thyroid C-cell tumors in rodent models
In the United States today, roughly three in four adults in midlife are living with at least one chronic health condition
In 2016, the prevalence of PD was 6.1 million globally, with a conservative estimate for numbers to double by 2050 [7]
Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
